



## Correction to: Brentuximab vedotin use in a jaundiced case with resistant Hodgkin lymphoma

Semra Paydas<sup>1</sup> · Ali Ogul<sup>1</sup> · Cem Mirili<sup>1</sup> · Serkan Gokcay<sup>1</sup>

Published online: 3 June 2019  
© Springer-Verlag GmbH Germany, part of Springer Nature 2019

**Correction to: Annals of Hematology 95(1): 145-146**  
<https://doi.org/10.1007/s00277-015-2493-x>

The original version of this article contained a mistake in one of the author names. Cem Irili should have been Cem Mirili.

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

---

The online version of the original article can be found at <https://doi.org/10.1007/s00277-015-2493-x>

---

✉ Semra Paydas  
sepay@cu.edu.tr

<sup>1</sup> Department of Medical Oncology, Cukurova University Faculty of Medicine, Balcali, Adana, Turkey